about   CII home   shop   checkout

2011 Speaker Biographies - Bioprocessing Summit

 

Instructor Bio’s

Joyce C. Chiu, M.B.A., Senior Project Leader, Honeywell Safety Products
Joyce ChiuJoyce has over 25 years in process engineering, product development and program management across diverse industries and technologies, including coated thin films for imaging and photography, microelectronic materials for semiconductors, hand-held displays for eBooks, hot-melt and injection molded products.  Her life science experience includes medical devices, single-use disposable systems for bioreactors and mixers, client services project management of interactive systems for clinical trials.  Joyce has expertise in material intensive product and process development, stage gate process, quality systems, statistics, six sigma, supply chain and operational excellence.  She holds a BS Chemical Engineering from Cornell University, an MBA from Babson College, summa cum laude, and a Certified Pharmaceutical Industry Professional (CPIP) credential by ISPE in 2010.

Susan Dana Jones, Ph.D., Vice President & Senior Consultant, BioProcess Technology Consultants, Inc.
Susan Dana JonesSusan Dana Jones is a seasoned biotechnology entrepreneur with experience in biopharmaceutical discovery, product development, and strategic planning. She co-founded two successful biotechnology companies and has managed multiple discovery and product development programs. Dr. Jones is a subject matter expert in cell line development and characterization and is a leader in applying the principles of Quality by Design (QbD) to early stage biopharmaceutical development programs. She currently advises clients on the advancement of product candidates from research through development. Dr. Jones also assists clients in the application of GMP regulations and preparation of regulatory submissions as well as performing technical due diligence in support of investors or mergers and acquisitions. Dr. Jones is a frequently invited spealer at industry conferences and symposia and also serves as a guest lecturer at Northeastern University. She is a member of the Board of Directors of Gene Solutions, LLC, the Symphogen A/S Scientific Advisory Board, the Editorial Advisory Board of BioProcess International. Prior to joining BioProcess Technology Consultants, Dr. Jones was Senior Vice President of Corporate Development at Serenex, Inc, where she worked with other senior managers to complete a $15M Series B financing. Prior to Serenex, she was Vice President of Product Development at Waratah Pharmaceuticals and previously held development and management positions of increasing responsibility at Peptimed Inc., Virus Research Institute (now Celldex Immunotherapeutics), IntraImmune Therapies Inc., and Dyax Corp. Dr. Jones received her Bachelor's degree from Harvard University, holds a Ph.D. in Genetics from the University of California, San Francisco, and performed post-doctoral research at the Dana-Farber Cancer Institute of Harvard Medical School.

Sheila G. Magil, Ph.D., Senior Consultant, BioProcess Technology Consultants, Inc.
Sheila MagilSheila Magil has over 20 years of experience developing manufacturing processes and analytical methods for small molecules, peptides, and biologics. She currently provides support to clients in the areas of analytical development, quality control, and quality assurance. Dr Magil also supports clients by performing regulatory compliance audits and assessing CMC related risks for products under consideration for acquisition. Prior to joining BioProcess Technology Consultants, Dr. Magil was Senior Manager, Analytical Development and Quality Control at Biomeasure, where she was responsible for creating the company's Biologics Quality Control department and managing external analytical and quality control for a new biologic product. She was also a member of the project team overseeing the construction of a new biologics manufacturing plant. As Vice President at Waratah Pharmaceuticals, Dr. Magil managed external process development and production of both peptide and protein therapeutics and also managed the toxicology testing of these products. At Alkermes, Dr. Magil was a Sr. Research Scientist in the formulation department working on new analytical methods for formulation development for several protein and peptide products. She also worked at Bion, Inc, and the Howard Hughes Medical Institute and the Massachusetts General Hospital providing direction to the core laboratory serving investigators at three institutions. Dr. Magil holds a Bachelor's degree in Chemistry from Carnegie-Mellon University and a Ph.D. in Biochemistry from the University of Minnesota Medical School.

Michael Betenbaugh, Ph.D., Professor, Chemical & Biomolecular Engineering, Whiting School of Engineering, Johns Hopkins University
Michael BetenbaughMichael Betenbaugh is Professor of Chemical and Biomolecular Engineering at Johns Hopkins University.  Dr. Betenbaugh received his Ph.D. in Chemical Engineering from the University of Delaware in 1988. That same year he joined Johns Hopkins University as an Assistant Professor in Chemical Engineering.

He rose through the ranks to Full Professor in 1997 and served as Chair of the Department, recently renamed Chemical and Biomolecular Engineering, from 2002 through 2005.  He is a researcher in the area of cell and metabolic engineering for eukaryotes in biotechnology specializing in protein expression, apoptosis, glycosylation, metabolism, cell cycle, and chaperones.  He has published numerous articles in both biology and bioengineering journals and received a number of patents which have been licensed to biotechnology companies.  He received the Young Investigator Award from National Science Foundation, the James Van Lanen Award from the American Chemical Society, and the Merck Cell Culture Engineering Award.  He has presented the Biochemical Engineering Award Lecture at the American Institute of Chemical Engineering and the Bayer Award Lecture in Biochemical Engineering, and has been inducted into Sigma Xi Research Honor Society and the American Institute of Medical and Biological Engineers.  He was a founding member of the Society of Biological Engineering and has served as an Associate Editor for the journal, Biotechnology and Bioengineering. He has participated in numerous international meetings in the field and was the program organizer of Cell Culture Engineering VIII and Biochemical Engineering XV.

Thomas Jostock, Ph.D., Technology Network Leader, Integrated Biologics Profiling, Novartis Pharma AGThomas JostockThomas Jostock is leading the New Technology Network and heading a laboratory in the Integrated Biologics Profiling Department of Novartis.

Thomas graduated from the University of Mainz in Germany, where he finished his PhD thesis in the field of cytokine research in 2001. Thereafter, he joined Dyax in Liege/Belgium, focusing on high throughput re-formatting of phage library derived Fabs to IgG antibodies and mammalian expression vectors before he took a position at the University of Braunschweig in Germany in 2003. During three years in Braunschweig, he was leading a research team working mainly on expression systems for antibodies and antibody fusion proteins. He is still giving lectures as a guest lecturer there. In 2006, Thomas joined Novartis in Basel /Switzerland and since then is worked on different technology development/evaluation projects as well as on NBE projects. In 2011, he was appointed New Technology Network Leader and is responsible for coordinating and conducting evaluation studies of external technologies as well as internal technology development programs within the Integrated Biologics Profiling Unit.

Ulrich Göpfert, Ph.D., Senior Research Scientist, Pharma Research and Early Development (pRED), Biologics Research, Roche Diagnostics GmbH

Ulrich GoepfertUlrich Göpfert is a Senior Reseach Scientist in the Cell Line and Molecule Development department at Roche. Dr. Göpfert received his Diploma and Ph.D. in Biochemistry from the University of Tübingen, Germany. In 2002 he joined the Biologics Research group of Roche in Penzberg. Since then he has been involved in the pre-clinical development of numerous therapeutic antibodies with a focus on lead identification, optimization and cell line development. His special interest is in the optimization of cell line selection processes for clinical supply and manufacturing.

 

Arnaud Perilleux, Scientist, Upstream Processing, Biotech Process Sciences, Merck Serono SAArnaud PerilleuxAfter getting his engineering degree in Biotechnology (ENSTBB, Bordeaux, France), Arnaud joined in 2008 the Merck Serono group as scientist in the cell culture department.

Arnaud is working on the development of a fed-batch platform for recombinant mammalian cell lines. He is participating in the optimization of cell culture conditions through the different scales, from micro scale up to 15KL bioreactor. He is leading the development of cell culture feeds and predictive methods for high throughput cell line selection and process development.

As a scientific expert in upstream, he is also involved early process adaptation for preclinical and phase I clinical studies. He is participating in the implementation of top of the art technologies, aiming to rationalize process knowledge, such as scientific data management, multivariate analysis, and design of experiments.

Jolanda Gerritsen, Ph.D., Technology Expert, Cell Line Development, Genmab B.V.Jolanda GerritsenSince 1993, she is involved in immunology, starting in the field of rheumatology and later the immunology field of transplantation, within this field she became specialized in the area of antibody research. In 2001, she joined the research and development department of Genmab BV. Since 2004 she is involved in cell line development. Currently she is Technology Expert, managing and leading the Cell Line Development unit and is responsible for the development, screening and selection of the final production cell lines which are transferred to a production facility. Next to this, she is responsible for the technology innovation projects within the Cell Line Development unit.



Christine DeMaria, Ph.D., Senior Scientist, Therapeutic Protein Expression, Genzyme Corp.
Christine DeMariaChristine DeMaria is a Senior Scientist in the Cell Line and Cell Culture Process Development group at Genzyme. Dr. DeMaria received her B.S. in Biology from Tufts University and her Ph.D. in Microbiology and Immunology from Wake Forest University School of Medicine. Since joining Genzyme in 2001, much of her work has focused on the optimization of cell line development platforms to streamline the generation of recombinant cell lines expressing therapeutic proteins. She has also played a major role in integrating new R&D initiatives into the early stage development of Genzyme's therapeutic candidates.

 

Chang Lu, Ph.D., Associate Professor, Chemical Engineering, Virginia TechChang LuDr. Chang Lu is currently an associate professor of Chemical Engineering at Virginia Tech. Dr. Lu obtained his B.S. in Chemistry with honors from Peking University, M.S. and PhD in Chemical Engineering from University of Illinois at Urbana-Champaign. He spent 2 years as a postdoc in Applied Physics at Cornell. From 2004 to 2009, he was an assistant and associate professor of Biological Engineering at Purdue University. Dr. Lu is interested in developing novel tools for biotechnology and cellular analysis. Among a number of honors, Dr. Lu is a recipient of Wallace Coulter foundation Early Career Award in Biomedical Engineering and NSF CAREER Award.

 

L. James Lee, Ph.D., Helen C. Kurtz Professor, Chemical and Biomolecular Engineering; Director, NSF Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymer Biomedical Devices (CANPBD), The Ohio State UniversityL. James LeeDr. L. James Lee is the Helen C. Kurtz Professor of Chemical and Biomolecular Engineering at The Ohio State University. He now serves as the Director of NSF Nanoscale Science and Engineering Center for Affordable Nanoengineering of Polymer Biomedical Devices (CANPBD), NSF IGERT Program on Molecular Engineering of Microdevices, and Ohio Center for Multifunctional Polymer Nanomaterials and Devices (CMPND) at Ohio State. He received a BS degree in chemical engineering from National Taiwan University and a Ph.D. degree in chemical engineering from University of Minnesota. Before joining The Ohio State University in 1982, he worked as a research scientist at General Tire and Rubber Company for 3 years. His research interest includes BioMEMS/NEMS, polymer and composite processing, and micro-/nanofabrication. He has more than 250 refereed journal publications, 25 patents and invention disclosures, and 10 book chapters. Dr. Lee received 14 Best Paper Awards in Society of Plastics Engineers and Society of Plastics Industry Annual Conferences in the last 20 years. He was elected as the Fellow of Society of Plastics Engineers in 2001 and Fellow of American Institute for Medical and Biological Engineering in 2006. Dr. Lee received the 2008 Malcolm E. Pruitt Award from Council of Chemical Research, 2008 Engineering/Technology Award and 2010 International Award from the Society of Plastic Engineers.

S. Patrick Walton, Ph.D., Associate Professor, Chemical Engineering & Materials Science, Michigan State UniversityS. Patrick WaltonS. Patrick Walton received his B.ChE. from Georgia Tech, where he began his biomedical research career in the Cardiovascular Fluid Dynamics Laboratory. He then attended MIT where he earned his M.S. and Sc.D. while working jointly with researchers at the Shriners Burns Hospital and Massachusetts General Hospital in Boston. While at MIT, he was awarded a Shell Foundation Fellowship and was an NIH Biotechnology Predoctoral Trainee. Upon completion of his doctoral studies, he joined the Stanford University Genome Technology Center, receiving an NIH Kirschstein post-doctoral fellowship. He joined Michigan State University in 2004 and his research is focused on the development of parallel analytical methods and the engineering of active nucleic acids (e.g., siRNAs) through mechanism-based design.

Dieter C. Gruenert, Ph.D., Professor, Department of Otolaryngology, Head and Neck Surgery, Department of Laboratory Medicine, University of California, San FranciscoDieter GruenertDieter C. Gruenert, Ph.D., is a Professor in the Departments of Otolaryngology-Head and Neck Surgery and Laboratory Medicine at UCSF as well as in the Department of Pediatrics at the University of Vermont. He received his Ph.D. in Biophysics from the University of California, Berkeley in 1982. His postdoctoral studies (1982-1984) were in the Department of Carcinogenesis at the Swiss Institute for Experimental Cancer Research. Prior to his present position, he was a Professor of Laboratory Medicine and the Co-Director of the Gene Therapy Core Center at UCSF (1992-1999), Professor of Medicine and Director, Division of Human Molecular Genetics at the University of Vermont (2000-2003), and a Senior Scientist and Head of the Stem Cell Research Program at the California Pacific Medical Center. His research focuses on human cell and molecular biology, nucleic acid delivery, and the development of gene, pharmacological, and cell-based therapies for the treatment of inherited diseases and cancer. His work has led to the development of novel diagnostic and oligo/polynucleotide-based therapeutic strategies to ameliorate disease pathology, as well as to numerous human epithelial cell systems now used in academic and industrial labs throughout the world. His recent work focuses on development of adult, embryonic, and induced pluripotent stem cells as well as development of novel approaches for generating immortalized cell systems to study disease progression and develop pharmacological, genetic, and/or regenerative therapies. He has > 150 publications and holds 5 patents. Dr. Gruenert is on the Editorial Boards of several scientific journals, and reviews grants for numerous public and private agencies both nationally and internationally including the NIH, the DOD, the VA, the Maryland and Connecticut Stem Cell Programs, the CF Foundation, the Medical Research Council, the German, Italian, and French CF Foundations, the Italian, German and French Ministry of Health/Science. He currently serves on the Ethics Committee (Chair, 2005-2008) and the Oligonucleotide-based Therapy Committee of the ASGCT and was awarded a European Respiratory Society Visiting Professorship at Necker Sick Children's Hospital in Paris (2009). He also holds an ongoing Visiting Professorship at Tor Vergata University in Rome. He has consulted for such biotech and pharma firms as Bayer, Boehringer Mannhein, Boehringer Ingelheim, Promega, and Discovery BioMed.

Susan Sharfstein, Ph.D., Associate Professor, Nanobioscience, College of Nanoscale Science and Engineering, University at AlbanySusan SharfsteinSusan Sharfstein received her B.S. in chemical engineering with honors from Caltech in 1987 and her Ph.D. in chemical engineering from UC Berkeley in 1993, receiving graduate fellowships from the university and the National Science Foundation. She received a National Institutes of Health Individual Research Service Award to pursue postdoctoral studies, initially at UC Berkeley and subsequently at the UCLA Medical School. Dr. Sharfstein joined the faculty at the University of Toledo in Bioengineering in 1996. In 2000, she received a National Science Foundation POWRE award to study glycobiology at the New York State Department of Health Wadsworth Laboratories. In 2001, she joined the Department of Chemical and Biological Engineering at Rensselaer Polytechnic Institute and in 2007 she received a dual appointment in Biology. In 2010, she joined the faculty at the College of Nanoscale Science and Engineering at the University at Albany as an Associate Professor of Nanobioscience. Professor Sharfstein received an NSF CAREER grant in 2000 for her work on hyperosmotic stress responses of hybridoma cells and the School of Engineering Education Excellence Award and the Class of 1951 Outstanding Teaching Award in 2007. She is the author of over 30 papers and book chapters in the field of mammalian cell biotechnology.

Rénald Gilbert, Ph.D., Research Officer, Biotechnology Research Institute, National Research Council Canada

Renald GilbertRénald Gilbert is the Leader of the Genomics and Gene Therapy Vectors Group at the Biotechnology Research Institute of the National Research Council of Canada (NRC-BRI) located in Montreal.  He is also an adjunct professor in the department of Neurology and Neurosurgery at McGill University. He completed his undergraduate studies at Laval University (Québec, Quebéc) and, in 1989, received an M.Sc. in biology from the same university. He obtained a Ph.D. in 1994 from the department of Biochemistry at McMaster University (Hamilton, Ontario).  After his postdoctoral training, first at the Weil Medical College of Cornell University in New York City, and then at the Montreal Neurological Institute, he joined the NRC-BRI in 2002 as a research officer.  In 2007 he became a group leader at the later institute.  An important research activity of his laboratory is to generate stable cell lines (mainly CHO cells) producing recombinant proteins.  His research interests focus on the development of improved systems (cell lines, promoters, viral and non-viral vectors) and methods to improve gene expression for recombinant protein production as well as gene therapy applications.

Alan Dickson, Ph.D., Professor, Biotechnology, and Director, Centre of Excellence in Biopharmaceuticals, Faculty of Life Sciences, The University of ManchesterAlan Dickson is currently Director of the Centre of Excellence in Biopharmaceuticals (CoEBP; http://www.coebp.ls.manchester.ac.uk) and is Professor of Biotechnology in the Faculty of Life Sciences at the University of Manchester (http://www.ls.manchester.ac.uk). Alan undertook his BSc and PhD at the University of Edinburgh, before moving to a Research Fellowship at the University of Kent and, subsequently, to the University of Manchester. His research has focused on the regulation of cell function (in terms of metabolic, protein and gene targets) in mammalian cells. The early 1990’s saw the start of series of fruitful collaborations with commercial partners in relation to mammalian cell hosts for protein harvest and this continues today through the Bioprocessing Research Industry Club (BRIC; http://www.bbsrc.ac.uk/business/collaborative-research/industry-clubs/bric/background.aspx) and via individual collaborations. The CoEBP acts to co-ordination all of the University of Manchester’s activities with the bioprocessing sector. Alan has been part of the senior management team of the Faculty of Life Sciences, as Dean for Graduate Education and, subsequently, Dean for Communications.

Paula Meleady, Ph.D., Senior Research Scientist and Programme Leader, Proteomics Core Facility, National Institute for Cellular Biotechnology (NICB), Dublin City UniversityPaula MeleadyI graduated with a PhD in Cell Biology from Dublin City University in 1997. I am a Senior Scientist at the NICB since 2001 and am currently Programme Leader of the Proteomics and Mass Spectrometry Core Facility at the NICB which is equipped with state-of-the-art proteomics and mass spectrometry equipment. My research interests include proteomic profiling and characterisation of recombinant mammalian cell lines (Chinese hamster ovary) in order to gain insights to improving productivity of biopharmaceuticals. This project is in collaboration with Pfizer at two sites - Andover, US and Grangecastle, Dublin, Ireland. I also have research interests in cancer, specifically uveal melanoma where we analyse patient tissue and vitreous fluid samples from the eye for biomarker discovery. I have co-authored over 35 peer-reviewed publications, 6 book chapters and 2 patents to date in research areas related to proteomics, bioprocessing and cancer.

Dr. Paula Meleady is currently the Senior Research Scientist and Program Leader in the Proteomics Core Facility at the National Institute for Cellular Biotechnology (NICB) at Dublin City University. Dr. Meleady received her B.Sc. in Biotechnology in 1993 and her Ph.D. in Biotechnology in 1997, both from Dublin City University. Dr. Meleady has published papers in 35 peer-reviewed journals, holds 2 patents, and has also written 6 book chapters. Her current research includes proteomic and phosphoproteomic analysis of recombinant mammalian cell lines (Chinese hamster ovary) in order to gain insights to improving productivity of biopharmaceuticals. This SFI-funded project is in collaboration with Pfizer (Grangecastle, Dublin and Andover, US). Dr. Meleady also collaborates on many of the clinical projects within the NICB using proteomic technologies (2D DIGE, SILAC, label-free LC-MS/MS) for biomarker discovery.

Matthew Gagnon, Process Engineer, Culture Process Development, BioProcess Research and Development, Pfizer, Inc.Matt GagnonMatt Gagnon joined Pfizer (legacy Wyeth) in 2007 after briefly working for a small startup medical device company, RenaMed Biologics. He is involved with the culture process development of both early and late stage biotherapeutics at Pfizer. In addition, Matt helped develop and optimize a technique to suppress lactate accumulation in CHO cell culture during the growth phase. He was later involved in implementing the lactate suppressing technique for the production of a biotherapeutic entering Phase III clinical trials. Matt holds a Bachelor of Engineering from McGill University in Montreal, Canada.

 

Sinyoung Park, Ph.D., Scientist, Process Development – Upstream, Ambrx, Inc.Sinyoung ParkSinyoung Park, Ph.D is a scientist at Ambrx who leads process development of the mammalian cell culture. Dr. Park brings over ten years of the industrial experience from biotechnology and pharmaceutical companies. Recently she worked in media development group at Xoma LLC where she improved the media feed strategy for multiple monoclonal antibody producing cell-lines and screened commercial media library using DOE(Design of Experiment) mixture design. Prior to this position she served as a senior scientist at Curagen Corporation overseeing technology transfer of the CHO(Chinese Hamster Ovary) cell culture process to a contract manufacturing company for the large-scale bioreactor production of monoclonal antibodies used for clinical-trial material. She has the extensive knowledge of fed-batch and perfusion bioreactors from Bayer Corporation during the production of Kogenate (blood clotting factor) using BHK (Baby Hamster Kidney) cells at process development laboratories and cGMP(current Good Manufacturing Practices) pilot plants.

Shuichi Takayama, Ph.D., Professor, Biomedical Engineering, Macromolecular Science and Engineering, College of Engineering, University of MichiganShuichi TakayamaShuichi Takayama is a Professor in the Department of Biomedical Engineering and the Macromolecular Science and Engineering Program at the University of Michigan. His research interests (B.S. and M.S. from the University of Tokyo in 1994, his Ph.D. degree in chemistry from the Scripps Research Institute in 1998) started with organic synthesis of molecules that mediate biological chemical communication. Subsequently he became interested in evaluating the function of synthesized molecules in engineered cellular-microsystems and pursued postdoctoral studies at Harvard University as a Leukemia and Lymphoma Society Fellow. His current research interests are Micro/nanofluidics and Cellular microenvironment engineering. He constructs microfluidic models of the body such as artificial oviducts for enhanced in vitro fertilization treatment, microtissue engineered models of lung injury, and models of cancer metastasis for drug testing. He also develops tools for high throughput 3D cell culture and cell micropatterning. Honors include The Ralph E. Powe Junior Faculty Award and The NSF Career Award. Ratmir Derda, Ph.D., Assistant Professor, Department of Chemistry, University of Alberta Dr. Ratmir Derda is currently an Assistant Professor in the Department of Chemistry at the Alberta Ingenuity Center for Carbohydrate Science. Dr. Derda earned his B.S. in Physics, Applied Mathematics and Biophysics at the Moscow institute of Physics and Technology in 2001 and then went on to receive his Ph.D. in Organic Chemistry at the University of Wisconsin-Madison in 2008. From 2008 to 2011, Dr. Derda worked as a Postdoctoral Fellow in the Department of Chemistry and Wyss Institute for Biologically Inspired Engineering at Harvard University. He has received numerous awards and grants for his research and has published 15 research papers in peer-reviewed journals. Dr. Derda also holds 3 patents. His most recent work is in 3D cell cultures where he has developed a simple method for generation and analysis of complex 3D tissue structures.

Ratmir Derda, Ph.D., Assistant Professor, Department of Chemistry, University of AlbertaDr. Ratmir Derda is currently an Assistant Professor in the Department of Chemistry at the Alberta Ingenuity Center for Carbohydrate Science. Dr. Derda earned his B.S. in Physics, Applied Mathematics and Biophysics at the Moscow institute of Physics and Technology in 2001 and then went on to receive his Ph.D. in Organic Chemistry at the University of Wisconsin-Madison in 2008. From 2008 to 2011, Dr. Derda worked as a Postdoctoral Fellow in the Department of Chemistry and Wyss Institute for Biologically Inspired Engineering at Harvard University. He has received numerous awards and grants for his research and has published 15 research papers in peer-reviewed journals. Dr. Derda also holds 3 patents. His most recent work is in 3D cell cultures where he has developed a simple method for generation and analysis of complex 3D tissue structures.

Thomas C. Killian, Ph.D., Professor, Physics and Astronomy, Rice UniversityThomas KillianThomas C. Killian received a BA in Physics in 1991 from Harvard University, and then attended Cambridge University on a Marshall Scholarship. At the Massachusetts Institute of Technology, he completed his PhD in atomic physics in 1999. At the National Institute of Standards and Technology, he initiated experiments on ultracold neutral plasmas, which are orders of magnitude colder than any neutral plasma ever produced before. In 2001, Dr. Killian joined the Department of Physics and Astronomy at Rice University, where he continues experiments on ultracold atoms and plasmas. His recent work also includes developing techniques to manipulate and probe biological structures with electromagnetic fields. He is a co-founder of Nano3D Biosciences, which is commercializing a technology for growing three-dimensional tissue for basic research, toxicology, and drug discovery. He is the recipient of a David and Lucille Packard Foundation Science and Engineering Fellowship, an Alfred P. Sloan Research Fellowship, and an Office of Naval Research Young Investigator Award.

Jianguo Yang, Ph.D., Principal Scientist, Commercial Cell Culture Development, Commercial Process Development, Biologic R&D, GenzymeJianguo YangDr. Yang is currently leading projects on late stage/ commercial cell culture development at Genzyme/ Sanofi-Aventis; prior to Genzyme, worked in MedImmune /Astrazeneca and Abbott labs. With over 20-year professional experience in cell line and cell culture development, and achieved world record high mammalian cell line productivity, Dr. Yang is an international recognized expert in cell line and cell culture development. He has authored numerous scientific and professional publications, presentations, and chaired several Industry professional conferences, and also is a member of Editor and Advisor Board for Bioprocess International Journal, and reviewer for Biotechnology and Bioengineering Journal. Dr. Yang holds both M.S. and Ph.D. degrees in molecular cell biology and biotechnology from the Illinois Institute of Technology.